An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa

As the coronavirus disease 2019 (COVID-19) pandemic continues and new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern emerge, the adaptive immunity initially induced by the first-generation COVID-19 vaccines starts waning and needs to be strengthened and broadened in...

Descripción completa

Detalles Bibliográficos
Autores principales: Vesin, Benjamin, Lopez, Jodie, Noirat, Amandine, Authié, Pierre, Fert, Ingrid, Le Chevalier, Fabien, Moncoq, Fanny, Nemirov, Kirill, Blanc, Catherine, Planchais, Cyril, Mouquet, Hugo, Guinet, Françoise, Hardy, David, Vives, Francina Langa, Gerke, Christiane, Anna, François, Bourgine, Maryline, Majlessi, Laleh, Charneau, Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9044714/
https://www.ncbi.nlm.nih.gov/pubmed/35484842
http://dx.doi.org/10.1016/j.ymthe.2022.04.016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9044714/
https://www.ncbi.nlm.nih.gov/pubmed/35484842
http://dx.doi.org/10.1016/j.ymthe.2022.04.016

Ejemplares similares